A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.
Public ClinicalTrials.gov record NCT05689164. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Long-term Follow-up Safety and Efficacy Study in Participants With Duchenne Muscular Dystrophy Who Have Received Fordadistrogene Movaparvovec in a Preceding Clinical Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to understand the safety and effects of an experimental gene therapy called fordadistrogene movaparvovec. We are seeking participants from previous Pfizer interventional studies. We will follow participants' experience in this study for 10 years after the end of their previous study. Participants will have 1 annual onsite visit and a few annual remote visits. The exact number of remote visits will be decided by their study doctor.
Study identification
- NCT ID
- NCT05689164
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 7 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 0 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 13, 2023 (Actual)
- Primary completion
- Sep 24, 2025 (Actual)
- Completion
- Sep 24, 2025 (Actual)
- Last update posted
- Oct 21, 2025
2023 – 2025
United States locations
- U.S. sites
- 12
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Reed Neurological Research Center | Los Angeles | California | 90095 | — |
| UCLA Children's Heart Center | Los Angeles | California | 90095 | — |
| UCLA Clinical Lab Services | Los Angeles | California | 90095 | — |
| UCLA Kameron Gait and Motion Analysis Laboratory (Westwood Rehabilitation Center) | Los Angeles | California | 90095 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| Duke Lenox Baker Children's | Durham | North Carolina | 27705 | — |
| Duke Children's Health Center | Durham | North Carolina | 27710 | — |
| University of Utah Imaging and Neurosciences Center | Salt Lake City | Utah | 84108 | — |
| University of Utah Hospital | Salt Lake City | Utah | 84112 | — |
| Primary Children's Hospital | Salt Lake City | Utah | 84113 | — |
| University of Utah Clinical Neurosciences Center | Salt Lake City | Utah | 84132 | — |
| University of Utah Craig H. Neilsen Rehabilitation Hospital | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05689164, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 21, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05689164 live on ClinicalTrials.gov.